Evidence map›Paper›PMID 30666133›Full record

ArticleOncoTargets and therapy2019

Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?

Yun Huang, Zeyu Zhang, Yufan Zhou, Jiajin Yang, Kuan Hu, Zhiming Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Recent therapeutics in hepatocellular carcinoma.American journal of cancer research · 2023
    Review
  15. [Research progress of microvascular invasion in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  16. [The consensus on tertiary prevention of primary liver cancer (2022 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yun HuangDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.
Zeyu ZhangDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.
Yufan ZhouDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.
Jiajin YangDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.
Kuan HuDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.
Zhiming WangDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 13808462382@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMicrovascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of HCC. If promptly treated, the recurrence rate can be reduced and the total survival time can be prolonged. The aim of this study is to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after curative hepatectomy.

methodsHCC patients who underwent hepatectomy and were pathologically diagnosed with MVI were retrospectively analyzed. Patients were divided into sorafenib group and control group. Sorafenib 400 mg, twice daily, was administered orally after surgery in the sorafenib group. The recurrence-free survival (RFS) and overall survival (OS) were observed during follow-up, and associated factors were analyzed using univariate and multivariate COX regression.

resultsThere was no significant difference in demographics, clinical staging, and tumor index between sorafenib group (16 patients) and control group (33 matched patients). The RFS and OS were both longer in the sorafenib group, and the 3-years RFS rates of the sorafenib group and control group were 56.3% (9 of 16) and 24.2% (8 of 33), respectively (

conclusionWe believe that using sorafenib therapy after curative hepatectomy in HCC patients with MVI is effective and beneficial as it can reduce recurrence and prolong the survival time.

Indexed as

hepatectomyhepatocellular carcinomamicrovascular invasionsorafenibsurvival rate

Identifiers

PMID30666133
PMCPMC6334782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.